Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅱ/Ⅲ Study to Evaluate Efficacy and Safety of Antaitavir Hasophate Capsules in Combination With Yiqibuvir Tablets in Adult Subject With Chronic HCV Infection

NCT05395416 is registered in ClinicalTrials.gov with Sunshine Lake Pharma Co., Ltd. as lead sponsor.

NCT NCT05395416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05395416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅱ/Ⅲ Study to Evaluate Efficacy and Safety of Antaitavir Hasophate Capsules in Combination With Yiqibuvir Tablets in Adult Subject With Chronic HCV Infection
Lead sponsor
Sunshine Lake Pharma Co., Ltd.
Phase
Phase 2/3
Overall status
Completed
Start date
June 21, 2021
Completion date
April 11, 2023
Enrollment
514 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hcv infection